Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelacarsen outcomes trial in established cardiovascular disease with elevated lipoprotein(a)
2019-001076-11Phase 3Active
- Sponsor
- Novartis
- Start
- Nov 2019
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cardiac morbidity and atherosclerotic disease comparing Pelacarsen with Placebo (2 arms). Primary endpoint: Expanded major adverse cardiovascular events in patients with lipoprotein(a) at least 70 mg/dL. Started Nov 2019; status: active.
02
Drugs
pelacarsen
03
Conditions
cardiac morbidityatherosclerotic disease
Beyond the preview
Go deeper on 2019-001076-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001076-11.